200 related articles for article (PubMed ID: 35469393)
61. [Potential cost effectiveness of a rotavirus vaccine in Chile].
Constenla D; O'Ryan M; Navarrete MS; Antil L; Rheingans RD
Rev Med Chil; 2006 Jun; 134(6):679-88. PubMed ID: 17130941
[TBL] [Abstract][Full Text] [Related]
62. Cost-Effectiveness of Rotavirus Vaccination for Under-Five Children in Iran.
Shakerian S; Moradi Lakeh M; Esteghamati A; Zahraei M; Yaghoubi M
Iran J Pediatr; 2015 Aug; 25(4):e2766. PubMed ID: 26396704
[TBL] [Abstract][Full Text] [Related]
63. Cost effectiveness of a pentavalent rotavirus vaccine in Oman.
Al Awaidy ST; Gebremeskel BG; Al Obeidani I; Al Baqlani S; Haddadin W; O'Brien MA
BMC Infect Dis; 2014 Jun; 14():334. PubMed ID: 24941946
[TBL] [Abstract][Full Text] [Related]
64. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.
Standaert B; Parez N; Tehard B; Colin X; Detournay B
Appl Health Econ Health Policy; 2008; 6(4):199-216. PubMed ID: 19382820
[TBL] [Abstract][Full Text] [Related]
65. Rotavirus vaccine product switch in Ghana: An assessment of service delivery costs, switching costs, and cost-effectiveness.
Owusu R; Mvundura M; Nonvignon J; Armah G; Bawa J; Antwi-Agyei KO; Amponsa-Achiano K; Dadzie F; Bonsu G; Clark A; Pecenka C; Debellut F
PLOS Glob Public Health; 2023; 3(8):e0001328. PubMed ID: 37556413
[TBL] [Abstract][Full Text] [Related]
66. The cost-effectiveness of rotavirus vaccination in Armenia.
Jit M; Yuzbashyan R; Sahakyan G; Avagyan T; Mosina L
Vaccine; 2011 Nov; 29(48):9104-11. PubMed ID: 21945959
[TBL] [Abstract][Full Text] [Related]
67. Socio-economic modelling of rotavirus vaccination in Castilla y Leon, Spain.
Pérez-Rubio A; Luquero FJ; Eiros Bouza JM; Castrodeza Sanz JJ; Bachiller Luque MR; de Lejarazu RO; Sánchez Porto A
Infez Med; 2011 Sep; 19(3):166-75. PubMed ID: 22037437
[TBL] [Abstract][Full Text] [Related]
68. Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness.
Rheingans R; Atherly D; Anderson J
Vaccine; 2012 Apr; 30 Suppl 1():A15-23. PubMed ID: 22520124
[TBL] [Abstract][Full Text] [Related]
69. Cost-effectiveness of interventions for HIV/AIDS, malaria, syphilis, and tuberculosis in 128 countries: a meta-regression analysis.
Silke F; Earl L; Hsu J; Janko MM; Joffe J; Memetova A; Michael D; Zheng P; Aravkin A; Murray CJL; Weaver MR
Lancet Glob Health; 2024 Jul; 12(7):e1159-e1173. PubMed ID: 38876762
[TBL] [Abstract][Full Text] [Related]
70. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
71. Estimated impact and cost-effectiveness of rotavirus vaccination in India: effects of geographic and economic disparities.
Rheingans R; Anderson JD; Anderson B; Chakraborty P; Atherly D; Pindolia D
Vaccine; 2014 Aug; 32 Suppl 1():A140-50. PubMed ID: 25091669
[TBL] [Abstract][Full Text] [Related]
72. Active Tuberculosis Screening via a Mobile Health App in Myanmar: Incremental Cost-Effectiveness Evaluation.
Htet KKK; Phyu AN; Zayar NN; Chongsuvivatwong V
JMIR Form Res; 2023 Nov; 7():e51998. PubMed ID: 37948119
[TBL] [Abstract][Full Text] [Related]
73. Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets.
Seo MK; Baker P; Ngo KN
Malar J; 2014 Feb; 13():66. PubMed ID: 24564883
[TBL] [Abstract][Full Text] [Related]
74. The cost-effectiveness of rotavirus vaccination in Australia.
Newall AT; Beutels P; Macartney K; Wood J; MacIntyre CR
Vaccine; 2007 Dec; 25(52):8851-60. PubMed ID: 18022735
[TBL] [Abstract][Full Text] [Related]
75. Cost-effectiveness of dengue vaccination in ten endemic countries.
Zeng W; Halasa-Rappel YA; Baurin N; Coudeville L; Shepard DS
Vaccine; 2018 Jan; 36(3):413-420. PubMed ID: 29229427
[TBL] [Abstract][Full Text] [Related]
76. Global Patterns of QALY and DALY Use in Surgical Cost-Utility Analyses: A Systematic Review.
Rios-Diaz AJ; Lam J; Ramos MS; Moscoso AV; Vaughn P; Zogg CK; Caterson EJ
PLoS One; 2016; 11(2):e0148304. PubMed ID: 26862894
[TBL] [Abstract][Full Text] [Related]
77. [Economic impact of rotavirus vaccination in Panama].
Constenla D; Ortega-Barría E; Rheingans RD; Antil L; Sáez-Llorens X
An Pediatr (Barc); 2008 Feb; 68(2):128-35. PubMed ID: 18341878
[TBL] [Abstract][Full Text] [Related]
78. Systematic review of rotavirus vaccination cost-effectiveness in high income settings utilising dynamic transmission modelling techniques.
Jesudason T; Rodarte A; Tordrup D; Carias C; Chen YH
Vaccine; 2023 Aug; 41(36):5221-5232. PubMed ID: 37479614
[TBL] [Abstract][Full Text] [Related]
79. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
[TBL] [Abstract][Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
